;PMID: 1341278
;source_file_471.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)sentence:[e:0..127] = [t:0..127]
;1)section:[e:131..201] = [t:131..201]
;2)sentence:[e:205..279] = [t:205..279]
;3)sentence:[e:283..453] = [t:283..453]
;4)sentence:[e:454..592] = [t:454..592]
;5)sentence:[e:594..645] = [t:594..645]
;6)sentence:[e:646..708] = [t:646..708]
;7)sentence:[e:709..856] = [t:709..856]
;8)section:[e:860..904] = [t:860..904]

;sentence 0 Span:0..127
;Surg Oncol  1992 Dec;1(6):405-11     Analysis of ras oncogene mutations in
;human squamous cell carcinoma of the head  and neck.
;[49..52]:gene-rna:"ras"
;[81..126]:malignancy:"squamous cell carcinoma of the head  and neck"
(SENT
  (FRAG (NNP:[0..4] Surg) (NNP:[5..10] Oncol) (CD:[12..16] 1992)
        (NNP:[17..21] Dec;) (CD:[21..22] 1) (NN:[22..23] -LRB-) (CD:[23..24] 6)
        (NN:[24..25] -RRB-) (::[25..26] :) (CD:[26..28] 40) (CD:[28..32] 5-11))
  (NP-HLN
    (NP (NN:[37..45] Analysis))
    (PP (IN:[46..48] of)
      (NP (NN:[49..52] ras) (NN:[53..61] oncogene) (NNS:[62..71] mutations)))
    (PP (IN:[72..74] in)
      (NP
        (NP (JJ:[75..80] human)
          (NML (JJ:[81..89] squamous) (NN:[90..94] cell))
          (NN:[95..104] carcinoma))
        (PP (IN:[105..107] of)
          (NP (DT:[108..111] the) (NN:[112..116] head) (CC:[118..121] and)
              (NN:[122..126] neck)))))
    (.:[126..127] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[0..127]::FRAG:NP:

;section 1 Span:131..201
;Nunez F, Dominguez O, Coto E, Suarez-Nieto C, Perez P, Lopez-Larrea C.
(SEC
  (FRAG (NNP:[131..136] Nunez) (NNP:[137..138] F) (,:[138..139] ,)
        (NNP:[140..149] Dominguez) (NNP:[150..152] O,) (NNP:[153..157] Coto)
        (NNP:[158..159] E) (,:[159..160] ,) (NNP:[161..166] Suare)
        (NNP:[166..173] z-Nieto) (NNP:[174..176] C,) (NNP:[177..182] Perez)
        (NNP:[183..185] P,) (NNP:[186..190] Lope) (NNP:[190..198] z-Larrea)
        (NNP:[199..201] C.)))

;sentence 2 Span:205..279
;Department of Otolaryngology, Hospital Central de Asturias, Oviedo, Spain.
(SENT
  (FRAG (NNP:[205..215] Department) (IN:[216..218] of)
        (NNP:[219..233] Otolaryngology) (,:[233..234] ,)
        (NNP:[235..243] Hospital) (NNP:[244..251] Central) (NNP:[252..254] de)
        (NNP:[255..263] Asturias) (,:[263..264] ,) (NNP:[265..271] Oviedo)
        (,:[271..272] ,) (NNP:[273..278] Spain) (.:[278..279] .)))

;sentence 3 Span:283..453
;The presence of proto-oncogene mutations at codons 12, 13 and 61 of the Ha-, 
;Ki-, and N-ras in primary head and neck squamous cell carcinoma are analysed
;in  this study.
;[314..323]:variation-event:"mutations"
;[327..336]:variation-location:"codons 12"
;[338..340]:variation-location:"13"
;[345..347]:variation-location:"61"
;[355..358]...[372..375]:gene-rna:"Ha-"..."ras"
;[361..364]...[372..375]:gene-rna:"Ki-"..."ras"
;[370..375]:gene-rna:"N-ras"
;[379..424]:malignancy:"primary head and neck squamous cell carcinoma"
(SENT
  (S
    (NP-SBJ-3
      (NP (DT:[283..286] The) (NN:[287..295] presence))
      (PP (IN:[296..298] of)
        (NP
          (NML (AFX:[299..304] proto) (HYPH:[304..305] -)
               (NN:[305..313] oncogene))
          (NNS:[314..323] mutations)))
      (PP-LOC (IN:[324..326] at)
        (NP
          (NP
            (NP
              (NML-2 (NNS:[327..333] codons))
              (CD:[334..336] 12))
            (,:[336..337] ,)
            (NP
              (NML-2 (-NONE-:[337..337] *P*))
              (CD:[338..340] 13))
            (CC:[341..344] and)
            (NP
              (NML-2 (-NONE-:[344..344] *P*))
              (CD:[345..347] 61)))
          (PP (IN:[348..350] of)
            (NP (DT:[351..354] the)
              (NML
                (NML (NN:[355..357] Ha) (HYPH:[357..358] -)
                  (NML-1 (-NONE-:[358..358] *P*)))
                (,:[358..359] ,)
                (NML (NN:[361..363] Ki) (HYPH:[363..364] -)
                  (NML-1 (-NONE-:[364..364] *P*)))
                (,:[364..365] ,) (CC:[366..369] and)
                (NML (NN:[370..371] N) (HYPH:[371..372] -)
                  (NML-1 (NN:[372..375] ras))))))))
      (PP (IN:[376..378] in)
        (NP (JJ:[379..386] primary)
          (NML (NN:[387..391] head) (CC:[392..395] and) (NN:[396..400] neck))
          (JJ:[401..409] squamous) (NN:[410..414] cell)
           (NN:[415..424] carcinoma))))
    (VP (VBP:[425..428] are)
      (VP (VBN:[429..437] analysed)
        (NP-3 (-NONE-:[437..437] *))
        (PP (IN:[438..440] in)
          (NP (DT:[442..446] this) (NN:[447..452] study)))))
    (.:[452..453] .)))

;sentence 4 Span:454..592
;Oncogene ras-specific sequences were amplified by the polymerase  chain
;reaction and probed with mutation specific oligonucleotide probes.
;[463..466]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ-1
      (NML
        (NML (NN:[454..462] Oncogene) (NN:[463..466] ras))
        (HYPH:[466..467] -) (JJ:[467..475] specific))
      (NNS:[476..485] sequences))
    (VP (VBD:[486..490] were)
      (VP
        (VP (VBN:[491..500] amplified)
          (NP-1 (-NONE-:[500..500] *))
          (PP (IN:[501..503] by)
            (NP-LGS (DT:[504..507] the) (NN:[508..518] polymerase)
                    (NN:[520..525] chain) (NN:[526..534] reaction))))
        (CC:[535..538] and)
        (VP (VBD:[539..545] probed)
          (NP-1 (-NONE-:[545..545] *))
          (PP-MNR (IN:[546..550] with)
            (NP
              (ADJP (NN:[551..559] mutation) (JJ:[560..568] specific))
              (NN:[569..584] oligonucleotide) (NNS:[585..591] probes))))))
    (.:[591..592] .)))

;sentence 5 Span:594..645
;Mutations were detected in 8 of 22 samples (36.3%).
;[621..636]:malignancy:"8 of 22 samples"
(SENT
  (S
    (NP-SBJ-1 (NNS:[594..603] Mutations))
    (VP (VBD:[604..608] were)
      (VP (VBN:[609..617] detected)
        (NP-1 (-NONE-:[617..617] *))
        (PP (IN:[618..620] in)
          (NP
            (NP (CD:[621..622] 8))
            (PP (IN:[623..625] of)
              (NP (CD:[626..628] 22) (NNS:[629..636] samples)
                (PRN (-LRB-:[637..638] -LRB-)
                  (NP (CD:[638..642] 36.3) (NN:[642..643] %))
                  (-RRB-:[643..644] -RRB-))))))))
    (.:[644..645] .)))

;sentence 6 Span:646..708
;No mutations were detected  on patients' peripheral blood DNA.
(SENT
  (S
    (NP-SBJ-1 (DT:[646..648] No) (NNS:[649..658] mutations))
    (VP (VBD:[659..663] were)
      (VP (VBN:[664..672] detected)
        (NP-1 (-NONE-:[672..672] *))
        (PP (IN:[674..676] on)
          (NP
            (NP (NNS:[677..685] patients) (POS:[685..686] '))
            (JJ:[687..697] peripheral) (NN:[698..703] blood) (NN:[704..707] DNA)))))
    (.:[707..708] .)))

;sentence 7 Span:709..856
;We found that histologically and clinically,  squamous cell carcinomas with
;or without a ras mutation do not differ  significantly from each other.
;[755..779]:malignancy:"squamous cell carcinomas"
;[798..801]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ (PRP:[709..711] We))
    (VP (VBD:[712..717] found)
      (SBAR (IN:[718..722] that)
        (S
          (ADVP (RB:[723..737] histologically) (CC:[738..741] and)
                (RB:[742..752] clinically))
          (,:[752..753] ,)
          (NP-SBJ
            (NP (JJ:[755..763] squamous) (NN:[764..768] cell)
                (NNS:[769..779] carcinomas))
            (PP (IN:[780..784] with) (CC:[785..787] or) (IN:[788..795] without)
              (NP (DT:[796..797] a) (NN:[798..801] ras) (NN:[802..810] mutation))))
          (VP (VBP:[811..813] do) (RB:[814..817] not)
            (VP (VB:[818..824] differ)
              (ADVP (RB:[826..839] significantly))
              (PP (IN:[840..844] from)
                (NP (DT:[845..849] each) (JJ:[850..855] other))))))))
    (.:[855..856] .)))

;section 8 Span:860..904
;PMID: 1341278 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[860..864] PMID) (::[864..865] :) (CD:[866..873] 1341278)
        (NN:[874..875] -LSB-) (NNP:[875..881] PubMed) (::[882..883] -)
        (NN:[884..891] indexed) (IN:[892..895] for)
        (NNP:[896..904] MEDLINE-RSB-)))
